DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Phase 3

Recruiting

Conditions: Familial Hypercholesterolemia - Heterozygous

Interventions: Drug: Inclisiran
Drug: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT06597019

Locations: 🇹🇷
Novartis Investigative Site, Ankara, Turkey
🇺🇸
Children's National Hospital, Washington, District of Columbia, United States
🇺🇸
UC San Francisco Medical Center, San Francisco, California, United States

and more 4 locations

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Phase 3

Recruiting

Conditions: Familial Hypercholesterolemia - Homozygous

Interventions: Drug: Inclisiran
Drug: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT06597006

Locations: 🇺🇸
UC San Francisco Medical Center, San Francisco, California, United States
🇺🇸
Childrens National Medical Center, Washington, District of Columbia, United States
🇺🇸
Washington Univ School Of Medicine, Saint Louis, Missouri, United States

and more 1 locations

A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)

Phase 2

Recruiting

Conditions: Lupus Erythematosus, Systemic
Lupus Nephritis

Interventions: Biological: rapcabtagene autoleucel Regimen 2
Biological: rapcabtagene autoleucel Regimen 1
Other: Standard of Care

First Posted Date: 2024-09-03

Last Posted Date: 2025-03-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 144

Registration Number: NCT06581198

Locations: 🇺🇸
UCSF, San Francisco, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University Of Iowa, Iowa City, Iowa, United States

and more 5 locations

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Phase 1

Recruiting

Conditions: Colorectal Cancer
Pancreatic Ductal Adenocarcinoma
Non-small Cell Lung Cancer
HR+/HER2- Ductal and Lobular Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: [68Ga]Ga-NNS309
Drug: [177Lu]Lu-NNS309

First Posted Date: 2024-08-20

Last Posted Date: 2025-04-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 124

Registration Number: NCT06562192

Locations: 🇨🇭
Novartis Investigative Site, Geneve 14, Switzerland
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 2 locations

Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants

Phase 1

Completed

Conditions: XXB750 in Healthy Participants

Interventions: Drug: XXB750
Other: Placebo

First Posted Date: 2024-08-16

Last Posted Date: 2024-08-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 77

Registration Number: NCT06558097

Locations: 🇺🇸
Novartis Investigative Site, Cypress, California, United States

A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

Recruiting

Conditions: Multiple Sclerosis

Interventions: Other: ofatumumab
Other: DMT category 1

First Posted Date: 2024-08-13

Last Posted Date: 2025-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 900

Registration Number: NCT06551519

Locations: 🇩🇪
Novartis Investigative Site, Tirschenreuth, Germany

A Study to Evaluate the Impact of Long-term Digital Education vs Standard of Care on LDL-C Levels in Post Myocardial Infarction Patients

Completed

Conditions: Myocardial Infarction

Interventions: Other: systematic educational intervention

First Posted Date: 2024-08-12

Last Posted Date: 2024-12-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT06548555

Locations: 🇨🇿
Novartis Investigative Site, Praha, Czechia

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Phase 1

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: ITU512
Drug: Placebo

First Posted Date: 2024-08-09

Last Posted Date: 2025-03-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 138

Registration Number: NCT06546670

Locations: 🇺🇸
Quotient Sciences Sea View, Miami, Florida, United States

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

Phase 1

Recruiting

Conditions: Metastatic Castration-Resistant Prostate Cancer

Interventions: Drug: AAA617
Drug: Gonadotropin-releasing hormone (GnRH) analogues
Drug: Gonadotropin-releasing hormone (GnRH) antagonists

First Posted Date: 2024-08-01

Last Posted Date: 2025-05-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 106

Registration Number: NCT06531499

Locations: 🇺🇸
Wash U School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States

and more 1 locations

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.

Phase 3

Recruiting

Conditions: Generalized Myasthenia Gravis

Interventions: Drug: Iptacopan
Other: Matching Placebo

First Posted Date: 2024-07-24

Last Posted Date: 2025-04-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 146

Registration Number: NCT06517758

Locations: 🇺🇸
Fullerton Neuro and Headache Ctr, Fullerton, California, United States
🇺🇸
Augusta University Georgia, Augusta, Georgia, United States
🇺🇸
SC3 Research Pasadena, Pasadena, California, United States

and more 24 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy